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Introduction
This study deals with the influence of capabilities and transaction 
costs on the adoption of governance structures in the manufactu-
ring stage of a productive system, following previous studies on the 
relationships between the approaches of organizational economics 
and competences (Hoetker, 2005; Nakamura & Odagiri, 2005; Wi-
lliamson, 1999). The research context is the pharmaceutical industry, 
which is highly dynamic in technological innovation and acquisi-
tions. In Brazil, we have observed institutional changes, government 
incentives and the growth of local laboratories (Silva & Ruiz, 2011).
The Transaction Cost Theory (TCT) argues that the firm is a nexus 
of contracts as a response to the increase of transaction costs using 
the market (Coase, 1937) and that agents present bounded ratio-
nality and may behave with opportunism. The unit of analysis is a 
transaction between productive stages, with the dimensions of fre-
quency, uncertainty, and asset specificity. The last of these is preva-
lent in empirical studies and shows the potential for the loss of earlier 
specific investment in the absence of the transaction. Thus, the choice 
of governance structure is a rational choice that aims to minimize 
the transaction costs arising from the hazard of opportunistic beha-
vior by the counterpart in the transaction (Williamson, 1991, 1999). 
This framework is useful for studying contractual arrangements in 
productive systems, such as franchising in retail markets or strategic 
partnerships in R&D activities (Ménard, 2006).
The capabilities approach has sought to understand the processes of 
adaptation and change in organizations in changing environments 
(Dosi, Nelson, & Winter, 2000; Teece, Pisano, & Shuen, 1997). The 
concept of routine is useful in this approach as a basic unit of va-
riation, selection, and replication that allows the firm to adapt to 
environmental changes. This process would explain the functioning 
of economic systems in the evolutionary theory proposed by Nelson 
and Winter (1982). There are ambiguities to apply the concept of rou-
tine in empirical studies (Becker, 2004).
To advance with a potential integration between the two approaches 
(Jacobides & Winter, 2005), we propose the following research ques-
tion: what is the influence of transaction costs and capabilities on the 
vertical integration of manufacturing in the pharmaceutical indus-
try? The general objective is to analyze the impact of transaction costs 
and competences on the choice between an internal and an external 
supplier for drug manufacturing in the pharmaceutical industry in 
Brazil. The specific objectives are the following. First, to develop a 
theoretical model with relationships between the constructs of expe-
rience, diversification, asset specificity, and vertical integration. Se-
cond, to measure the constructs with secondary data for products of 
the pharmaceutical industry. Third, to test the construct validity of 
the proposed model. Fourth, to evaluate the hypotheses of the model 
for the relationships between the constructs. 
Concerning transaction costs, we measured asset specificity with two 
dimensions: the presence of differential aspects in the product (Bige-
low & Argyres, 2008), and the share of products with some attributes 
in the firm’s portfolio. To examine the capabilities, we adopted the 
constructs of experience and diversification. The first of these was 
measured using the time for which the firm or group had operated in 
the industry (Bataglia & Meirelles, 2009; Bataglia, Silva, & Klement, 
2011; Dosi et al., 2000). 
We adopted the diversification construct considering the view of the 
firm as a bundle of capabilities (Kogut & Zander, 1992), and our in-
tention to measure it by the share of the firm´s product portfolio in 
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the set of product types available in the market. This concept is a na-
rrower one than the deployment of the knowledge base of the firm in 
different markets (Klein & Lien, 2009).
As the pharmaceutical industry has grown, firms adopted the hierar-
chy as the predominant governance structure in the various stages 
of the value chain, generating large and vertically integrated corpo-
rations. From the 1980s onwards, strategic alliances increased, first 
abroad and, later, in Brazil (Estrella & Bataglia, 2013; Macedo & 
Bataglia, 2012; Powell, White, Koput, & Owen-Smith, 2005). At the 
manufacturing stage, the motivation for a firm with traditional pro-
ducts to outsource would be its competition with companies that offer 
similar products. When adopting outsourcing at this stage, firms may 
rely on multiple vendors for common industrial requirements. Thus, 
companies that are focused on innovative products can reduce their 
production costs and increase their margins in the period between 
the launch of the product and the entry of similar or generic products 
(Polastro, 1999).
To get the registry as a drug producer in Brazil, companies must ope-
rate according to the “good manufacturing practices” defined by the 
National Agency of Sanitary Surveillance (ANVISA, 2010). Firms 
need to achieve tight control of their processes, and this can lead to 
vertical integration becoming predominant. If the company outsour-
ces particular stages, the regulator must also approve the contractor. 
This option requires a close relationship with the contractor to per-
form tasks from the design of processes to the quality management of 
the final products. 
We assumed that the “make or buy” strategic decision (Bataglia & Yu, 
2008) in manufacturing corresponds to the choice between vertical 
integration and a strategic alliance for outsourcing. We can measure 
this by the presence of vertical integration at each stage of production, 
or by an index measuring the proportion of vertical integration at all 
stages, following Hoetker (2005) and Nakamura and Odagiri (2005).
The study has five sections. The second presents the theoretical fra-
mework, and the third explains the methods used in this research, 
including the data and procedures. We show the results in the fourth 
section, and we include the discussion and final considerations in the 
last part.
Theoretical Framework and Hypotheses
This section presents a conceptual model for the explanation of go-
vernance structures in the manufacturing stage, based on the tran-
saction cost and capabilities approaches. Williamson (1999) suggests 
that the attributes of a transaction could explain the choice of generic 
governance structure, while aspects of organizational learning could 
also influence some aspects of the chosen governance structure. The 
theme of governance structures covers an extensive research field, es-
pecially for hybrid structures (Ménard, 2004). However, we limited 
our analysis of governance structures with a frequent variable in em-
pirical studies of TCT: the choice between internal (make) and exter-
nal (buy) supplier (Hoetker, 2005). 
The second limiting choice was our focus on transactions at the manu-
facturing stage, concentrating on its relevance in infant industries like 
the pharmaceutical industry in Brazil. Nogueira (2011) observed this 
process with the Brazilian laboratory Aché, which initially grew with 
the support of partnerships with multinational companies for plant 
acquisitions and drugs licensing. In recent years the company has accu-
mulated manufacturing expertise and resources to increase its market 
share and generate revenues to conduct product innovation activities.
We developed the conceptual model following the work of Jacobi-
des and Winter (2005). They argue that the distribution of producti-
ve capabilities between firms in an industry defines the difference in 
vertical scope, with transaction costs presenting a moderating effect. 
The approach in the present model is similar, but we consider only 
the operating capabilities of the firm owning the product. We chose 
this approach considering the adoption of the product as the unit of 
analysis and the influence of the firm’s capabilities on a specific tran-
saction. The model of Jacobides and Winter (2005) refers to the analy-
sis of a population of firms in an industry to measure the distribution 
of capabilities. Nogueira and Bataglia (2012) proposed a conceptual 
model to explain the choice of supplier for manufacturing, based on 
transaction costs and the capabilities of the firm owning the product. 
Drawing upon the work of Dosi et al. (2000), Kogut and Zander 
(1992), and Jacobides and Winter (2005), we expect that the organi-
zational knowledge stored and expressed in routines to be built by the 
limits of the firm, particularly in the manufacturing stage. According 
to this approach, the environment of the firm allows groups of emplo-
yees to exchange experiences and to promote organizational learning. 
This conditions can help the definition of an appropriate level of spe-
cialization in the different stages of the value chain. 
Henderson and Cockburn (1994) found two relevant types of capabi-
lities for R&D activities in the pharmaceutical industry: component 
and architectural capabilities. Component capabilities refer to skills 
in disease categories and specific issues that support the development 
of medicines. Architectural capabilities address to the ability to com-
bine the disciplines and areas of therapeutic classes within the firm. 
For these authors, the experience could be useful for measuring both 
types of capabilities. 
Since the focus of this work is the manufacturing stage, we assume 
that experience might be relevant and measured it by how long the 
firm has run in the industry. Bigelow and Argyres (2008) consider 
the influence of the firm’s experience in the industry on the choice 
of governance structure. These authors argue that as the firm gains 
experience, it will specialize in activities with higher participation in 
the total cost of the value chain of the product. In this sense, they ex-
pect a tendency to operate on product development and to outsource 
manufacturing and distribution. Along these lines, we propose the 
following hypothesis:
Hypothesis 1 (H1). The experience of the firm in the pharmaceutical 
industry has a negative relationship with vertical integration in the 
manufacturing stage of the product.
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The diversification of a company reflects the range of different types 
of delivered products. In the pharmaceutical industry, we can descri-
be a product by its pharmaceutical form, therapeutic class, and regu-
latory category. We expect that successful pharmaceutical companies 
have a minimum efficient size and offer a diverse portfolio of pro-
ducts, to achieve economies of scale in their production systems and 
risk management in their R&D to deliver new products to the market 
(Bogner, 1996). A diversified portfolio can influence the operatio-
nal capabilities by exposing this functional area to a broad range of 
pharmaceutical forms. In this sense, this characteristic of a company’s 
capabilities might encourage it to internalize its manufacturing. Fo-
llowing this reasoning, we derive the hypotheses below: 
Hypothesis 2 (H2). The diversification of the firm in the attributes 
of its products has a positive relationship with vertical integration 
in the manufacturing stage of the products. 
Asset specificity is an attribute often discussed in the TCT literature as 
a relevant factor in the choice of governance structure. The rationale 
is that the investment in transaction-specific assets favours the adop-
tion of the hierarchy to coordinate the transaction rather than con-
tracting with external suppliers. The existence of a transaction-speci-
fic asset resulting from investment by one partner leaves this agent in 
a disadvantageous position and subject to opportunistic behavior by 
the other partner (Williamson, 1991). Under these conditions, there 
is a tendency for the agent to internalize the transaction for the firm. 
The hypothesis is as follows:
Hypothesis 3 (H3). Asset specificity in the manufacturing stage of a 
product in the pharmaceutical industry has a positive relationship 
with vertical integration at that stage. 
The literature is scarce on the relationship between transaction costs 
and operational capabilities and it presents some difficulties for re-
searchers, because each of them address a different object, respecti-
vely the transaction and the firm. However, we can assume that the 
transactions carried out by the firm can influence its productive ca-
pabilities. According to Jacobides and Winter (2005), the productive 
capabilities rest on the firm’s general and specific knowledge of how 
to do things and also involve specific investments in equipment and 
the training and retention of the key personnel required to put that 
knowledge to work. 
The moderating function of transaction costs on the relationship 
between the distribution in an industry of the productive capabilities 
of firms and the vertical scope is discussed by Jacobides and Winter 
(2005). They offer two hypotheses. First, if capabilities are dissimilar 
along the value chain, then potential gains from trade across the firm’s 
boundaries exist, and so a reduction in transaction costs will lead to 
substantial disintegration. Second, if capabilities are similar along the 
value chain, then there are no expected gains from trade across the 
firm’s boundaries, and so a reduction in transaction costs will not lead 
to substantial disintegration. 
Argyres and Zenger (2012) presented a critical view of this approach. 
They recognize that the empirical research in the literature corrobo-
rates this straightforward application of the comparative logic on ca-
pabilities to boundary choices. However, they argue that transaction 
costs and competences intertwine dynamically as the determinants 
of firms’ boundaries. In the original phase of forming capabilities, 
transaction cost considerations have relevance to firms in deciding 
whether to retain, develop or sell off the competences. Argyres and 
Zenger focus on how organizations build their capabilities in their 
early and later boundary decisions and consider that, besides serendi-
pity, the distribution of competences across firms and their suppliers 
reflects the transaction costs of operating in the past. 
The aim of the model and the hypotheses we have presented is to 
deepen the comprehension of the role of capabilities and transaction 
costs in the choice of the boundaries of the firm in the manufacturing 
function. To test these hypotheses, we have developed a structural 
equation model (Williams, Edwards, & Vandenberg, 2003).
Methods
This section presents the methodological procedures followed in the 
study. We designed and conducted the research with the data from 
the public records on drugs in Brazil. The text contains the descrip-
tion of the procedures, involving the definition of the unit of analysis, 
the measurement of the constructs and the strategy for data analysis.
Concerning the research universe, we chose the set of drugs regis-
tered and approved for marketing in Brazil by the National Agency 
for Sanitary Surveillance (ANVISA). Within this universe, the object 
of analysis is the drug manufacturing transaction. According to the 
definition of ANVISA (2010), manufacturing involves the stages of 
production, fractioning, and packaging. For this object, we conside-
red the constructs of Asset Specificity, Experience, Diversification, 
and Vertical Integration. We present the indicators of the constructs 
in the next section.
With these constructs, the unit of analysis is the drug’s registration 
in ANVISA, and we opted for the collection and analysis of the total 
population of records in the official database called Bulário Eletrô-
nico (<http://www.anvisa.gov.br/datavisa/fila_bula/index.asp>). In 
the new database created for the research, we defined the product 
as the combination of the active principle with the pharmaceutical 
form, since a drug may present two or more forms, and there may be 
different levels of vertical integration for each one. For example, the 
drug Acheflan (Aché Laboratories) is one case in ANVISA but gene-
rates two products in the new database: Acheflan cream and Acheflan 
aerosol. We followed four steps to construct our dataset. First, the 
extraction of data on the drug registration from ANVISA, second, 
the generation of records of products. The third step was a search and 
collection of the time for which the firms that own the products and 
their groups have operated, and fourth, a calculation of the indicators 
of the latent variables and constructs, as presented in the next section. 
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Measurement of Latent Variables
We created indicators for the latent variables with drug registration 
data in ANVISA. Starting with the product, we searched other sou-
rces and collected the name of the firm and its owner or holding 
corporation, defined as the group and the experience, measured by 
the length of time for which the firm and the group, respectively, 
had been in operation. Thus, this study provides a methodological 
contribution to the measurement of capabilities and transaction 
costs based on secondary data for products in the pharmaceutical 
industry. 
Considering the information available in the official database, the in-
dicators of the drug used in this study were the vertical integration, 
the pharmaceutical form, and therapeutic class. The pharmaceutical 
form is a physical aspect, such as pill, liquid or cream. There are 62 
forms in ANVISA, and we converted each one in dichotomous varia-
bles of the product. 
The drug’s function for diseases or human organs is the therapeutic 
class, which we measured by 72 dichotomous indicators (Classes). 
Besides that, we created 13 anatomic classes, resulting from the ag-
gregation of similar therapeutic classes by organs and systems of the 
human body (Agg Class). This method is an international standard 
for drug classification, the Anatomic Therapeutic Chemical (ATC) 
system of the World Health Organization (WHO, 2011).
We measured Vertical Integration by an endogenous variable with the 
same name and eight indicators. The drug label identifies the firm 
responsible for each stage of manufacturing: production, fractioning 
and packaging. We used the choice between vertical integration and 
an outsourcing contract (which, by definition, was a strategic allian-
ce contract) (Ménard, 2004, 2006). The dichotomous indicators for 
the firm are “Make Prod in Firm” (internal supplier for production), 
“Make Pott in Firm” (internal supplier for fractioning) and “Make 
Pack in Firm” (internal supplier for packaging). Similarly, the indica-
tors for the group are “Make Prod in Group,” “Make Pott in Group” 
and “Make Pack in Group”. The scalar indicators were the number 
of stages in which the internal supplier (or, respectively, the group) 
participated, as a percentage of the total number of stages (“Vertical 
Integ in Firm” and “Vertical Integ in Group”).
Two indicators measured the variable Experience. First, “Firm Time,” 
the time in years for which the firm had operated in Brazil. Second, 
“Group Time,” the time in years for which the oldest firm in the group 
had operated. 
For the variable Diversification, we adopted four indicators at the firm 
and group level, being two related to forms and two for therapeutic 
classes. First, “Firm in Forms,” the number of distinct forms of the 
firm divided by the total number of forms. Second, “Group in Forms,” 
the similar indicator at the group level. Third, “Firm in Classes,” the 
number of distinct classes of the firm divided by the total number of 
classes. Fourth, “Group in Classes,” the correspondent indicator for 
the level of the group. 
We measured the variable Asset Specificity with three dichotomous 
indicators. We transformed the list of 62 pharmaceutical forms from 
ANVISA (2011) into dichotomous measures assigned to the product. 
We then created new indicators called “aggregate forms” by grouping 
the original forms with common attributes related to asset specificity. 
First, “Release Attribute in Agg Form,” the aggregate form composed 
of original forms with specific attributes related to releasing the drug 
in the human body. Second, “Pack Attribute in Agg Form,” the aggre-
gate form composed of original forms with specific attributes related 
to fractioning or packaging. Third, “Any Attribute in Form,” an indi-
cator of an original form with any specific attribute. 
Strategy for Data Analysis
We evaluated the data with three steps. The first was the central ten-
dency and dispersion in the population with descriptive statistics. The 
second was the partial correlation coefficients between the indicators. 
The third was the analysis of a structural equation model, with evalua-
tion of the measurement model and the structural relationships to test 
the hypotheses using the partial least squares (PLS) method. The PLS 
method is a technique of structural equation modeling to analyze the 
causal relations between constructs. This technique does not require 
multivariate normality in the distribution of the variables (Wold, 1985).
We constructed the variables Vertical Integration, Experience, Diversi-
fication and Asset Specificity reflectively with their indicators (Edwards 
& Bagozzi, 2000). The coefficients of the structural model represent 
standardized regression coefficients, and the loads of the latent varia-
bles associated with the constructs are the factor loadings. The signifi-
cance was determined by the Bootstrap method with 1000 repetitions. 
A value of p < 0.05 (t > = 1.96) was used for significance tests.
Results
In this section, we present and discuss the results of the data analysis. 
First, we show the general characteristics of the data with the struc-
ture of the indicators. The following part contain the evaluation of 
the descriptive statistics and correlations. In the last part, we present 
the results of the proposed structural model. In a preliminary data 
investigation, there were no missing values. We evaluated outliers 
with the Mahalanobis distance test, resulting in the identification and 
exclusion of 40 cases. 
Descriptive Statistics and Correlations
The database contains 1566 products associated with 111 firms consoli-
dated into 88 groups. For Vertical Integration we found the equal avera-
ges for production and fractioning in the firms at 61.00%, lower than the 
value for groups, 83.00%. The same is true for packing inside the firms 
(73.00%) and the groups (90.00%). For the scalar aggregate indicators, 
the value for firms (64.75%) is also lower than that for groups (85.55%). 
The data for Experience reveals that the average time for which the 
firms had operated in Brazil (50 years) is less than this indicator for 
the groups (148 years), reflecting the relatively short history of ma-
nufacturing in Brazil compared with the age of foreign pharmaceutical 
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groups. The results for Diversification showed an average share of 
25% of the total number of forms for the firms and 53.23% for the 
groups. This difference reflects the function of a group to increase 
diversification in forms. The share of the total number of classes is 
25% for the firm and 32.7% for the group, revealing that a group has 
a relatively minor effect on this diversification, perhaps because of 
the higher costs involved in the development of the capabilities in 
different therapeutic classes. 
For Asset Specificity, the average frequencies for the aggregate forms 
are 10% for the packing attribute and 30% for the release attribute. 
The shares for the aggregate class are 30.75% for firms and 25.12% for 
groups. We analyzed the partial correlations between the indicators 
and found values between 0.30 and 0.60, and in some cases values 
greater than 0.80, which allows the application of multivariate analy-
sis, such as factorial analysis using structural equations.
Construct Validity
In this section, we discuss the validity of the scale used to measure 
the constructs. We used tests of reliability and convergent and dis-
criminant validity with the software SmartPLS 3.2.7 (Ringle, Wende, 
& Becker, 2015). Figure 1 shows the measurement model estimated 
by PLS after the validation stage. The ovals include the variable and 
the percentage of variance explained by the relationships with other 
variables. We present the loads and t values in the arrows for latent va-
riables and indicators. The criteria for acceptance of an indicator was 
the statistical significance (p < 0.05, t > = 1.96) with the value superior 
to 0.45 of the load. Most of the loads are above 0.60 and exhibit p < 
0.01 (t > = 2.576), indicating its adaptation. 
In re-specification of the model, we eliminated the indicators Make 
Pott in Firm and Vertical Integ in Firm because of multicollinearity, 
as indicated by offensive loads. The second round of model calcula-
tion excluded the indicators Make Pott in Group (load = -0.174, t = 
0.073), Make Pack in Group (load = 0.111, t = 0.058) and Vertical 
Integ in Group (load = 0.220, t = 0.037) because of the lack of signi-
ficance of the loads.
Concerning Experience, both indicators showed significance. It is no-
teworthy that Group Time has a higher load than Firm Time. This 
result may reflect the high share of foreign products in the population 
(70%) since all belong to firms with a higher average age than the 
domestic firms. For Diversification, all the indicators showed loads 
higher than 0.600 and appropriate significance. Asset Specificity had 
loads suitable for the first-order variables used in its measurement. 
Form Specificity showed a load about twice as large as that for the 
variable Class Specificity. 
The reliability of the constructs was based on three criteria: reliability 
of lower-level variables; composite reliability (the construct) (accep-
table values > 0.70); and average variance extracted (AVE) (acceptable 
values > 0.50) (Chin, 1998). We assessed the reliability of the variables 
related to the constructs by the magnitude of the respective factor 
loads. Most loads must be at least 0.60, and ideally, they should be at 
or above 0.70 (Chin, 1998; Falk & Miller, 1992). We can see in Figure 
1 that the only one item present a load bellow 0.60 (Make Prod in 
Group) and eight loads are higher than 0.90. Table 1 shows the com-
posite reliability and average variance extracted (AVE). Both meet the 
established suitability criteria.
Figure 1 – Mensuration model re-specified with coefficients*
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The analysis presented in Table 2 supports the convergent validity for 
the constructs of the model, as it indicates higher loads in absolute 
Table 1
Measurement of construct reliability
Variable AVE Composite Reliability 
Experience 0.666 0.795
Diversification 0.851 0.958
Asset Specificity 0.555 0.784
value for the indicators related to the latent variables, as predicted by 
the model, with smaller loads for the other variables (Chin, 1998). 
We tested the discriminant validity using the method of Fornell & 
Larcker (1981). All constructs in the model showed discriminant va-
lidity, as the square root of the AVE for the latent variables, displayed 
in bold on the diagonal of the correlation matrix (Table 3), are higher 
than the other latent variables.
Table 2
Cross loads for evaluation of convergent validity
Indicator Asset Specificity Diversification Experience Vertical Integration
Pack Attribute in Agg Form 0,606 0,052 0,060 -0,070
Release Attribute in Agg Form 0,917 -0,042 -0,057 -0,180
Any Attribute in Form 0,676 0,044 0,037 -0,075
Firm in Classes -0,011 0,935 0,572 -0,135
Group in Classes -0,023 0,911 0,468 -0,096
Firm in Forms 0,024 0,939 0,592 -0,117
Group in Forms -0,002 0,904 0,463 -0,082
Firm Time -0,032 0,139 0,676 -0,128
Group Time -0,001 0,660 0,935 -0,267
Make Prod in Firm -0,175 -0,146 -0,247 0,933
Make Pack in Firm -0,139 -0,092 -0,260 0,906
Make Prod in Group -0,069 -0,004 -0,046 0,584
Table 3
Cross correlation of first level latent variables
Asset Specificity Diversification Experience Vertical Integration
Asset Specificity 0,745
Diversification -0,003 0,922
Experience -0,013 0,577 0,816
Vertical Integration -0,166 -0,120 -0,261 0,823
Analysis of Structural Model
As shown in Figure 1, the explained variance for the dependent variables of 
the model (R2) is below but near 10%, revealing an adequate predictive power 
Table 4
Test of hypotheses of the model
Hypothesis Proposed Effect Regression Coefficient Observed t Value Hypothesis Supported
Effect on Vertical Integration (R2 = 0.098)
H1: Experience  Vertical Integration - -0.289 13.397 Yes
H2: Diversification  Vertical Integration + 0.046a 1.747 No
H3: Asset Specificity  Vertical Integration + -0.108 2.663 No
    a Non-significant
of the PLS model (Falk & Miller, 1992). In Table 4, we present the hypotheses 
and test results, where the structural factors were significant except for H2. 
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Hypothesis H1 proposes a negative relationship between Experience 
and Vertical Integration. We found a negative and significant structu-
ral coefficient, which does support this hypothesis. 
Hypothesis H2 establishes a positive relationship between Diversifi-
cation and Vertical Integration. The model shows a positive and not 
significant structural coefficient, which do not support the hypothesis 
related to the view of the firm or group as a bundle of capabilities. To 
deep the comprehension on this result, we investigated the presen-
ce of mediating and moderating effects of the constructs Experience 
and Asset Specificity in this relation. We tested more five new models, 
whose results are in the following paragraphs. 
The second model tested the influence of Diversification on Vertical 
Integration, grouping just these two constructs, resulting in a nega-
tive structural coefficient (-0.134) with significance (t = 6.84) and a 
lower explanation power for Vertical Integration (R2 = 0.018) than the 
first model of the Figure 1. The third model tested the simultaneous 
influence of Diversification and Asset Specificity on Vertical Integra-
tion, keeping just these three constructs. The structural coefficient 
for the relation between Diversification and Vertical Integration was 
lower than the second model, but still negative (-0.123) and signifi-
cant (t = 5.262). The structural coefficient for the relation between As-
set Specificity and Vertical Integration was also negative (-0.168) and 
significant (t = 7.417), and this model showed a higher explanation 
power (R2 = 0.043) for Vertical Integration than the second one. These 
results indicate the inexistence of mediating effect of Asset Specificity 
on the relationship between Diversification and Vertical Integration.
The fourth model tested the relationships of Diversification and Expe-
rience on Vertical Integration. The explanation power of this model for 
Vertical Integration was higher than the second and third model (R2 = 
0.071). The structural coefficient for the relation between Diversifica-
tion and Vertical Integration was positive (0.047) and not significant 
(t = 1.669), while the structural coefficient for the relation between 
Experience and Vertical Integration was negative (-0.292) and strongly 
significant (t = 14.245). These results show a clear mediating effect of 
Experience on the relation between Diversification and Vertical Inte-
gration. Thus, the original negative and significant effect of Diversifica-
tion on the Vertical Integration of the second model disappeared. 
Along these lines, we may add the following new propositions in this work: 
Proposition 1 (P1). The diversification of the firm in the attributes of its 
products has a negative relationship with the vertical integration in the 
manufacturing stage of the products in the pharmaceutical industry.
Proposition 2 (P2). The experience mediates the relation between 
diversification of the firm and the vertical integration in the ma-
nufacturing stage of the products in the pharmaceutical industry. 
The fifth and sixth models tested the moderation effect of experience 
and asset specificity on the relationship between Diversification and 
Vertical Integration. The results showed the inexistence of modera-
ting effects.
Hypothesis H3 suggests a positive relationship between Asset Speci-
ficity and Vertical integration. The model presented a negative and 
significant coefficient, which contradicts the proposed hypothesis. It 
appears that the manufacturing does not have the strategic relevan-
ce to justify vertical integration when asset specificity increases. This 
result suggests a low perceived risk of opportunistic behavior in the 
outsourcing of manufacturing stage. 
Discussion and Final Considerations
The study aimed to analyze the influence of transaction costs and ca-
pabilities on vertical integration for the manufacturing stage in the 
pharmaceutical industry in Brazil. The objective was to contribute to 
the research agenda on the relationship between the transaction costs 
and capabilities approaches, particularly about the adoption of a go-
vernance structure in a production system. While the TCT has been 
successful in confirming its hypotheses in empirical studies, the capabi-
lities approach still faces some difficulties in the measurement of cons-
tructs, but there has been a growing application of some aspects of this 
approach in the area of strategy. In this section, we present the main 
implications of the results of the testing of the hypotheses of this work. 
The result of the test of hypothesis H1 indicated that, in the phar-
maceutical industry, the higher the experience, the lower the vertical 
integration. In the pharmaceutical industry, pioneer firms had an in-
tegrated structure because of the industry regulation and the low ini-
tial dissemination of capabilities among agents. As time passed with 
the firms operating and the spread of the capabilities throughout the 
industry, it seems that these firms focused on activities with relatively 
higher participation in value generation. In this sense, the firms li-
mited their operations in the most relevant stages in the value chain, 
considering the participation in the total cost of the product, outsou-
rcing the manufacturing stages with less relevance on these criteria, 
whenever suppliers are available in the market. We can also see this 
behavior in the automotive and telecom industry. 
We rejected the hypothesis H2 (a positive influence of Diversification 
on Vertical Integration) and analysed some alternative models to in-
vestigate the mediating and moderating effects of the experience and 
asset specificity in this relation. The results of these models showed 
a clear mediating effect of Experience on the relationship between 
Diversification and Vertical Integration and the inexistence of mode-
rating effects. The effect of the inclusion of Experience was the cance-
lling the original negative effect of Diversification and the increase of 
the total explanation power of the model for the Vertical Integration. 
By this result the influence of diversification on vertical integration 
occurs only in presence of the experience. There are some theoretical 
reasons for this statement. First, the experience must help the firms in 
this industry to decide the level of vertical integration for the portfolio 
of products. The operation time favour the firm to concentrate its ac-
tivities on the more relevant stages in value creation of each product. 
As the firm increases the diversification in the product portfolio, the 
experience will support the decision on vertical integration, balancing 
production costs and the participation on the revenue of each product. 
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The second reason for the influence of experience on diversifica-
tion is the building of capabilities to manage the production lines, 
regarding therapeutic classes and the administration forms of the 
products. For each movement of launch products with diverse the-
rapeutic class and form, increasing the diversification, the capability 
to manage the production lines will direct the decisions to explore 
the available productive assets with adaptations, to invest in new 
equipment’s or to contract an external supplier for the new product 
if available. 
The third reason for the dependence of diversification on experience 
in vertical integration decisions is the capability to manage the strate-
gic alliances related to the manufacturing stage. Since the experience 
with the management of earlier alliances is central to increase this 
capability, the decision of vertical integration when the firm raises the 
diversification is affected by the operation time. 
The fourth reason of the relationship of diversification and experience 
is that both are associated with scale of production. We expect the 
increase of diversification with experience, in order to reduce the 
market risks with a balanced portfolio with innovative and older pro-
ducts. In this sense, the increase of diversification could be associated 
to the scale of production. The decision of vertical integration when 
the scale is raising depends on the availability of capital for new plants 
and the profitability of establishing strategic alliances for the manu-
facturing stage. 
One contribution of the study is that we could highlight the differen-
ce in the kind of capabilities measured in each proxy, since diversifi-
cation measures the number of different competences of the firm in 
form and class, while experience relates to the learning curve related 
with productivity gains.
We found a negative relationship between asset specificity and ver-
tical integration (hypothesis H3). The rejection of the hypothesis, 
rather than suggesting the invalidity of TCT, seems to be due to as-
pects of the industry and of the transaction in question. The result 
seems to indicate that the drug manufacturing transaction has low 
strategic value in the value chain of the pharmaceutical industry. 
We suspect that companies tend to outsource the manufacturing of 
products with specific attributes, preferring in some cases to use the 
capabilities of a partner rather than those of the internal supplier, as 
the TCT prediction. The result indicates that these specific attributes 
do not appear to represent sources of transaction costs arising from 
the risk of opportunistic behavior by partners. We can argue that a 
strategic alliance at the manufacturing stage for products with specific 
attributes presents a low risk that the service provider will hold up the 
supply. The reason for this assumption is the appropriating structure 
for the R&D investment made by agents in this industry, centred on 
the patenting of active principals of the drugs.
One limitation of the study relates to its exploratory nature. Attempts 
to establish relationships between the transaction costs and capabili-
ties approaches are still at a nascent stage, although empirical eviden-
ce is already accumulating about the possibilities of a complementary 
application of the theories. However, the literature has not yet reached 
a consensus on the feasibility of a more general and integrated theory. 
We suggest that the results and the implications derived from this 
work require a precautionary interpretation in view of the characte-
ristics of the indicators and the structural model used. Our attempt to 
use secondary data about products as a starting point to generate data 
about firms may contain biases related to capabilities. We could not 
evaluate the origin of products, whether developed internally or came 
into the portfolio by mergers or acquisitions. The second limitation of 
this study relates to the distribution of cases between domestic and fo-
reign firms and groups. The population that we tested reflects a mar-
ket segment with a predominance of new drugs mostly produced by 
foreign companies. Future studies should also evaluate the influence 
of the categories of innovative and generic on the vertical integration 
of manufacturing stage. 
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